BR112016021206A2 - - Google Patents
Info
- Publication number
- BR112016021206A2 BR112016021206A2 BR112016021206A BR112016021206A BR112016021206A2 BR 112016021206 A2 BR112016021206 A2 BR 112016021206A2 BR 112016021206 A BR112016021206 A BR 112016021206A BR 112016021206 A BR112016021206 A BR 112016021206A BR 112016021206 A2 BR112016021206 A2 BR 112016021206A2
- Authority
- BR
- Brazil
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014092101 | 2014-04-25 | ||
| JP2014-092101 | 2014-04-25 | ||
| PCT/JP2015/062520 WO2015163448A1 (ja) | 2014-04-25 | 2015-04-24 | ４環性化合物を高用量含有する製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112016021206A2 true BR112016021206A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2017-08-15 |
| BR112016021206B1 BR112016021206B1 (pt) | 2022-07-12 |
Family
ID=54332608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016021206-1A BR112016021206B1 (pt) | 2014-04-25 | 2015-04-24 | Composição farmacêutica, contendo composto tetracíclico em dose elevada e seu método de produção |
Country Status (19)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE046402T2 (hu) * | 2009-06-10 | 2020-03-30 | Chugai Pharmaceutical Co Ltd | Tetraciklusos vegyületek |
| KR101362589B1 (ko) | 2010-08-20 | 2014-02-12 | 추가이 세이야쿠 가부시키가이샤 | 4환성 화합물을 포함하는 조성물 |
| US10668075B2 (en) | 2012-09-25 | 2020-06-02 | Chugai Seiyaku Kabushiki Kaisha | RET inhibitor |
| WO2015008844A1 (ja) | 2013-07-18 | 2015-01-22 | 大鵬薬品工業株式会社 | Ｆｇｆｒ阻害剤耐性癌の治療薬 |
| US20160193210A1 (en) | 2013-07-18 | 2016-07-07 | Taiho Pharmaceutical Co., Ltd. | Antitumor drug for intermittent administration of fgfr inhibitor |
| AR100187A1 (es) * | 2014-04-25 | 2016-09-14 | Chugai Pharmaceutical Co Ltd | Composición farmacéutica que contiene un inhibidor de alk (quinasa de linfoma anaplásico) |
| TWI765410B (zh) | 2014-08-08 | 2022-05-21 | 日商中外製藥股份有限公司 | ４環性化合物的非晶質體的用途 |
| MX390320B (es) | 2015-01-16 | 2025-03-20 | Chugai Pharmaceutical Co Ltd | Farmaco de combinacion. |
| HUE051074T2 (hu) | 2015-03-31 | 2021-03-01 | Taiho Pharmaceutical Co Ltd | 3,5-diszubsztituált benzol alkinil vegyület kristálya |
| KR20180118719A (ko) | 2016-03-04 | 2018-10-31 | 다이호야쿠힌고교 가부시키가이샤 | 악성 종양 치료용 제제 및 조성물 |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| PL3616696T3 (pl) * | 2017-04-28 | 2025-05-05 | Astellas Pharma Inc. | Kompozycja farmaceytczna do podawania doustnego zawierająca enzalutamid |
| HUE067430T2 (hu) | 2018-03-19 | 2024-10-28 | Taiho Pharmaceutical Co Ltd | Nátrium-laurilszulfátot tartalmazó gyógyászati készítmény |
| BR112020025499A2 (pt) | 2018-06-29 | 2021-03-09 | Chugai Seiyaku Kabushiki Kaisha | Composição farmacêutica que compreende agente básico pouco solúvel |
| EP3848361B1 (en) | 2018-09-04 | 2025-01-22 | Chugai Seiyaku Kabushiki Kaisha | Method of producing tetracyclic compound |
| AR121187A1 (es) * | 2019-12-27 | 2022-04-27 | Chugai Pharmaceutical Co Ltd | Método para clasificar, evaluar o fabricar lauril sulfato de sodio de materia prima o formulación farmacéutica que lo contiene |
| WO2021134647A1 (zh) * | 2019-12-31 | 2021-07-08 | 广州帝奇医药技术有限公司 | 一种持续释放组合物及其制备方法 |
| US20240115578A1 (en) * | 2021-01-29 | 2024-04-11 | Chugai Seiyaku Kabushiki Kaisha | Drug composition for treating pediatric cancers |
| EP4424313A4 (en) | 2021-10-28 | 2025-07-09 | Chugai Pharmaceutical Co Ltd | PREPARATION OF SYRUP |
| WO2025045901A1 (en) | 2023-08-31 | 2025-03-06 | F. Hoffmann-La Roche Ag | Treatment of non small cell lung cancer with alectinib |
| WO2025104045A1 (en) | 2023-11-15 | 2025-05-22 | F. Hoffmann-La Roche Ag | Alectinib for the treatment of alk fusion-positive solid or cns tumours |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4918630B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1970-07-29 | 1974-05-11 | ||
| US5028433A (en) | 1988-11-30 | 1991-07-02 | Banyu Pharmaceutical Co., Ltd. | Readily absorbable drug formulation of NB-818 |
| JPH0667840B2 (ja) * | 1988-11-30 | 1994-08-31 | 萬有製薬株式会社 | Ｎｂ―８１８の易吸収性製剤 |
| JPH0892090A (ja) | 1994-07-26 | 1996-04-09 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| ATE172463T1 (de) | 1994-08-04 | 1998-11-15 | Hoffmann La Roche | Pyrrolocarbazol |
| JPH09202728A (ja) * | 1995-12-11 | 1997-08-05 | Hisamitsu Pharmaceut Co Inc | 固形製剤 |
| AU703395B2 (en) | 1996-05-01 | 1999-03-25 | Eli Lilly And Company | Halo-substituted protein kinase C inhibitors |
| EP1178988B1 (en) | 1999-05-14 | 2007-02-28 | The Australian National University | Compounds and therapeutic methods |
| WO2002043704A1 (en) | 2000-12-01 | 2002-06-06 | Kyowa Hakko Kogyo Co., Ltd. | Composition improved in solubility or oral absorbability |
| GB0030417D0 (en) | 2000-12-13 | 2001-01-24 | Pharma Mar Sa | An anticancer lead compound isolated from a New Zealand ascidian |
| FR2841138B1 (fr) | 2002-06-25 | 2005-02-25 | Cll Pharma | Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation |
| US7807197B2 (en) | 2002-09-28 | 2010-10-05 | Mcneil-Ppc, Inc. | Composite dosage forms having an inlaid portion |
| BRPI0407757A (pt) | 2003-02-28 | 2006-02-14 | Inotek Pharmaceuticals Corp | derivados de benzamida tetracìclica e métodos de uso dos mesmos |
| SI1454992T1 (sl) | 2003-03-07 | 2006-10-31 | Ist Naz Stud Cura Dei Tumori | Test kinaze anaplasticnega limfoma, reagenti in sestavki le-teh |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| AU2004259012C1 (en) | 2003-07-23 | 2012-08-02 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| US7378414B2 (en) | 2003-08-25 | 2008-05-27 | Abbott Laboratories | Anti-infective agents |
| WO2005035516A1 (ja) | 2003-10-10 | 2005-04-21 | Ono Pharmaceutical Co., Ltd. | 新規縮合複素環化合物およびその用途 |
| PT1687305E (pt) | 2003-11-21 | 2008-10-17 | Novartis Ag | Derivados de 1h-imidazoquinolina como inibidores de proteína quinase |
| AU2004296905A1 (en) | 2003-12-12 | 2005-06-23 | Merck Frosst Canada Ltd | Cathepsin cysteine protease inhibitors |
| CN1934082A (zh) | 2004-03-19 | 2007-03-21 | 斯皮德尔实验股份公司 | 有机化合物 |
| AU2005230847B2 (en) | 2004-03-31 | 2012-11-08 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| CN101023064B (zh) | 2004-08-26 | 2011-02-16 | 辉瑞大药厂 | 作为蛋白激酶抑制剂的对映异构体纯的氨基杂芳基化合物 |
| US7091202B2 (en) | 2004-09-15 | 2006-08-15 | Bristol-Myers Squibb Company | 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators |
| GB0423964D0 (en) * | 2004-10-28 | 2004-12-01 | Jagotec Ag | Dosage form |
| GB0517329D0 (en) | 2005-08-25 | 2005-10-05 | Merck Sharp & Dohme | Stimulation of neurogenesis |
| KR20080056288A (ko) | 2005-11-07 | 2008-06-20 | 아이알엠 엘엘씨 | Ｐｐａｒ 조절제로서의 화합물 및 조성물 |
| KR101146852B1 (ko) | 2005-12-05 | 2012-05-16 | 화이자 프로덕츠 인크. | Ｃ?ｍｅｔ／ｈｇｆｒ 억제제의 다형체 |
| US7601716B2 (en) | 2006-05-01 | 2009-10-13 | Cephalon, Inc. | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors |
| US8063225B2 (en) | 2006-08-14 | 2011-11-22 | Chembridge Corporation | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
| CN101516403B (zh) * | 2006-09-14 | 2013-10-02 | 安斯泰来制药株式会社 | 口腔崩解片及其制备方法 |
| EP1914240B1 (en) | 2006-10-11 | 2009-12-02 | Astellas Pharma Inc. | EML4-ALK fusion gene |
| CA2598893C (en) | 2006-10-11 | 2012-04-10 | Astellas Pharma Inc. | Eml4-alk fusion gene |
| WO2008051547A1 (en) | 2006-10-23 | 2008-05-02 | Cephalon, Inc. | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors |
| EP2142551B1 (en) | 2007-04-17 | 2015-10-14 | Bristol-Myers Squibb Company | Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors |
| TWI389893B (zh) | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | 二（芳胺基）芳基化合物 |
| KR101567763B1 (ko) | 2007-07-20 | 2015-11-12 | 네르비아노 메디칼 사이언시스 에스.알.엘. | 키나제 억제제로서 활성인 치환된 인다졸 유도체 |
| CN101932325B (zh) | 2007-11-30 | 2014-05-28 | 新联基因公司 | Ido抑制剂 |
| US20090214648A1 (en) * | 2008-02-15 | 2009-08-27 | Malathi Kandakatla | Pharmaceutical formulations comprising ibuprofen and diphenhydramine |
| JP5554699B2 (ja) | 2008-03-13 | 2014-07-23 | 第一三共株式会社 | オルメサルタンメドキソミルを含む製剤の溶出性の改善 |
| JP4707073B2 (ja) * | 2008-09-30 | 2011-06-22 | アステラス製薬株式会社 | アトルバスタチン経口投与用粒子状医薬組成物 |
| EA201190235A1 (ru) | 2009-05-07 | 2012-05-30 | Астразенека Аб | Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750 |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| HUE046402T2 (hu) | 2009-06-10 | 2020-03-30 | Chugai Pharmaceutical Co Ltd | Tetraciklusos vegyületek |
| GB0910046D0 (en) | 2009-06-10 | 2009-07-22 | Glaxosmithkline Biolog Sa | Novel compositions |
| US20110311625A1 (en) * | 2010-06-14 | 2011-12-22 | Amruth Gowda Doddaveerappa | Solid dosage forms of fenofibrate |
| KR101362589B1 (ko) | 2010-08-20 | 2014-02-12 | 추가이 세이야쿠 가부시키가이샤 | 4환성 화합물을 포함하는 조성물 |
| TWI564008B (zh) | 2010-09-30 | 2017-01-01 | 鹽野義製藥股份有限公司 | 難溶性藥物之溶解性改善製劑 |
| JP5006987B2 (ja) | 2010-11-22 | 2012-08-22 | 中外製薬株式会社 | ４環性化合物を含む医薬 |
| WO2012138532A2 (en) * | 2011-04-06 | 2012-10-11 | Dow Global Technologies Llc | Process for producing cellulose derivatives of high bulk density and good flowability |
| US20130267552A1 (en) * | 2012-04-04 | 2013-10-10 | IVAX International GmbH | Pharmaceutical compositions for combination therapy |
| US10668075B2 (en) | 2012-09-25 | 2020-06-02 | Chugai Seiyaku Kabushiki Kaisha | RET inhibitor |
| CA2923667A1 (en) * | 2013-09-09 | 2015-03-12 | Triact Therapeutics, Inc. | Cancer therapy |
| RU2016146119A (ru) | 2014-04-25 | 2018-05-29 | Чугаи Сейяку Кабусики Кайся | Новый кристалл тетрациклического соединения |
| AR100187A1 (es) * | 2014-04-25 | 2016-09-14 | Chugai Pharmaceutical Co Ltd | Composición farmacéutica que contiene un inhibidor de alk (quinasa de linfoma anaplásico) |
| CN110960500B (zh) | 2014-06-18 | 2022-10-14 | 豪夫迈·罗氏有限公司 | 包含非离子性表面活性剂的新型药物组合物 |
| TWI765410B (zh) | 2014-08-08 | 2022-05-21 | 日商中外製藥股份有限公司 | ４環性化合物的非晶質體的用途 |
-
2015
- 2015-04-24 AR ARP150101248A patent/AR100187A1/es not_active Application Discontinuation
- 2015-04-24 WO PCT/JP2015/062520 patent/WO2015163448A1/ja active Application Filing
- 2015-04-24 CN CN201580020724.5A patent/CN106456651A/zh active Pending
- 2015-04-24 KR KR1020167031396A patent/KR102412321B1/ko active Active
- 2015-04-24 JP JP2015530792A patent/JP5859712B1/ja active Active
- 2015-04-24 MX MX2016013809A patent/MX386901B/es unknown
- 2015-04-24 SG SG10202009484WA patent/SG10202009484WA/en unknown
- 2015-04-24 CA CA2946518A patent/CA2946518C/en active Active
- 2015-04-24 CN CN202111292754.5A patent/CN113975243A/zh active Pending
- 2015-04-24 TW TW109145714A patent/TWI771839B/zh active
- 2015-04-24 KR KR1020227020701A patent/KR102478887B1/ko active Active
- 2015-04-24 RU RU2016145057A patent/RU2724056C2/ru active
- 2015-04-24 TW TW111104939A patent/TWI831128B/zh active
- 2015-04-24 EP EP15783124.9A patent/EP3135287B1/en active Active
- 2015-04-24 PL PL15783124.9T patent/PL3135287T3/pl unknown
- 2015-04-24 AU AU2015250574A patent/AU2015250574B2/en active Active
- 2015-04-24 EP EP24171823.8A patent/EP4397659A3/en active Pending
- 2015-04-24 US US15/304,133 patent/US10350214B2/en active Active
- 2015-04-24 TW TW104113204A patent/TWI720943B/zh active
- 2015-04-24 SG SG11201607623XA patent/SG11201607623XA/en unknown
- 2015-04-24 BR BR112016021206-1A patent/BR112016021206B1/pt active IP Right Grant
- 2015-04-24 MY MYPI2016001752A patent/MY189913A/en unknown
- 2015-04-24 ES ES15783124T patent/ES2994202T3/es active Active
- 2015-04-24 MY MYPI2022000663A patent/MY200583A/en unknown
- 2015-04-24 CA CA3140565A patent/CA3140565C/en active Active
- 2015-04-24 RU RU2020119391A patent/RU2020119391A/ru unknown
- 2015-12-16 JP JP2015244821A patent/JP6129942B2/ja active Active
-
2016
- 2016-09-19 ZA ZA2016/06447A patent/ZA201606447B/en unknown
- 2016-10-13 IL IL248363A patent/IL248363B/en active IP Right Grant
- 2016-10-20 MX MX2021012300A patent/MX2021012300A/es unknown
-
2019
- 2019-07-11 US US16/508,760 patent/US11433076B2/en active Active
-
2020
- 2020-09-10 AU AU2020230293A patent/AU2020230293B2/en active Active
-
2021
- 2021-05-12 IL IL283152A patent/IL283152B2/en unknown
-
2022
- 2022-07-29 US US17/877,542 patent/US20220378800A1/en not_active Abandoned
- 2022-08-26 US US17/896,758 patent/US20230105990A1/en active Pending
-
2024
- 2024-03-15 AR ARP240100647A patent/AR132148A2/es unknown
Also Published As
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/04/2015, OBSERVADAS AS CONDICOES LEGAIS |